The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|August 24, 2021
Rheumatoid Arthritis Quiz: Focus on Therapeutics
Author(s)Lana Pine
How much do you know about the treatment of patients with rheumatoid arthritis? Find out now with our quiz.
Advertisement
Which is the most important consideration when treating rheumatoid arthritis?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement